Bayer's Delaware Court Win Meets a Green Milestone in Spain as the Stock Sags

Delaware judge lets Bayer's Monsanto mRNA patent suits proceed; Spanish Aspirin site wins decarbonization award; shares drop 5.1%.

Bayer's week has been a study in contrasts: a favorable courtroom ruling in the United States, a decarbonization award in Spain, and a share price that refused to celebrate either.

A US federal judge in Delaware has rejected motions from Pfizer, BioNTech and Moderna seeking early dismissal of patent lawsuits filed by a Bayer unit inherited from Monsanto. Reuters reported the decision on Monday. The suits concern intellectual property covering messenger RNA processes used in the manufacture of COVID-19 vaccines, and the ruling clears the way for the cases to proceed on their original track. For the Monsanto entity, the outcome keeps alive its ability to press the patent claims through the normal litigation process.

Delaware is only one front. In Missouri, a separate trial has opened in which three plaintiffs allege that Monsanto failed to adequately test the herbicide Roundup before putting it on the market. That case rests on product safety rather than warning labels — a legal question the US Supreme Court did not directly address in an earlier ruling. Bayer disputes the allegations.

A Spanish Plant Bids Farewell to Carbon

On the industrial side, Bayer's push to green its manufacturing base notched a visible win. The company received an award this week under the Convive prizes run by energy supplier Iberdrola for the decarbonization of active-ingredient production for the painkiller Aspirin at its Langreo site in Spain. Bayer is putting EUR 17 million into the Asturian facility. The new energy system is entering test operation and is slated to move into regular service before the end of 2026. According to the company, the site will become the first fully decarbonized pharmaceutical production facility in Spain, avoiding more than 6,500 tonnes of carbon dioxide annually. Process-related emissions from making the long-established medicine will fall to nearly zero, and Bayer positions the plant as one of the first decarbonized pharmaceutical production sites anywhere in Europe. The project is intended to keep the location competitive over the long haul and to prepare it for tighter environmental rules.

New Products, New Partners

Bayer is also pressing ahead in over-the-counter medicines. In the United States it launched MiraSOFT, a stool softener based on the active ingredient docusate sodium, sold exclusively through CVS Pharmacy in more than 7,000 stores and via the chain's online channel. Management, meanwhile, is hunting for fresh momentum in its own drug development. Under a showcase run by the Bayer Co.Lab initiative, Asian biotech companies presented their RNA technologies at a specialist conference in Boston, where representatives from Bayer's business development and licensing teams scouted possibilities for joint projects and partnerships.

Analysts Split, Shares Slide

Against that operational backdrop, the equity has drawn little comfort. Deutsche Bank Research rated Bayer "Buy" on Tuesday with a price target of 60 euros. Analyst Virginie Boucher-Ferte expects operating sales growth of 1.3 percent year on year in the third quarter. Investors will get the actual figures on November 3, 2026, when Bayer reports third-quarter 2026 results.

The market's mood has been far less constructive. The stock shed 5.1 percent yesterday to close at 45.31 euros, weighed down in part by a cautious read from JPMorgan. Analyst Richard Vosser flagged early consensus estimates for the third quarter as likely too high. Lingering legal risk added to the wariness, with the new Missouri Roundup proceeding keeping product safety and design questions in play while a verdict was pending. In today's trading the shares are down another 1.1 percent at 44.79 euros, roughly 17 percent below their 52-week high.

On the leadership front, Dr. Christoph Koenen has taken over as Chief Medical Officer of the pharmaceutical division. The company also launched the Menopause Advocacy and Policy Alliance together with global partners from science, health policy and industry. Whether operations can offset the legal drag is the question investors will carry into the November numbers.